Servier and Aitia Announce a New Collaboration Focused on Parkinson’s Disease

Aitia‘s Gemini Digital Twins will help identify subpopulations of patients who could respond favorably to Servier’s LRRK2 in development treatment Suresnes (France), 08 January 2024 – Servier, an independent international pharmaceutical group, and Aitia, the leader in the application of causal AI and Digital Twins, have strengthened today their partnership by signing a new contract […]

Charles River and Aitia Join Forces to Harness AI and Gemini Digital Twins in Advancing Neurodegenerative and Oncology Research

Charles River Laboratories has entered into an agreement granting Aitia access to its artificial intelligence-powered drug solution platform. The objective is to expedite the development of multiple therapy programs targeting neurodegenerative diseases and oncology. Read more on the recent collaboration between Charles River and Aitia, in Fierce Biotech article. Full article available here.

Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology

Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the agreement  WILMINGTON, Mass. & Somerville, Mass. – November 13, 2023: Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia, a leader in the application of Causal AI and […]